Effects of YM529, a novel minodronic acid, on adjuvant arthritis in rats
S. Masuda-Aiba, T. Shinozaki, K. Takagishi
Department of Orthopaedic Surgery, Gunma University Faculty of Medicine
ABSTRACT
Objective
The effects of a new third-generation bisphosphonate, YM529, on both the development and treatment of adjuvant arthritis were investigated in rats.
Methods
Five-week-old Lewis rats with adjuvant arthritis were prophylactically and therapeutically treated with 0.001, 0.01 and 0.05 mg/kg/day of YM529 and the arthritis scores were measured. Soft X-ray and histological findings were compared to those of the control group. Body weights were also measured.
Results
YM529 suppressed the severity of adjuvant arthritis in a dose-dependent manner when used as either a prophylactic or therapeutic drug. Administration of the drug had little effect on body weight.
Conclusion
YM529 may act on arthritic joints locally to prevent inflammation. However, further experiments are necessary to elucidate the underlying mechanisms.
Key words
Adjuvant arthritis, bisphosphonates, YM529, cytokines.
Please address correspondence and reprint requests to: T. Shinozaki, MD, PhD, Department of Orthopaedic Surgery, Gunma University Faculty of Medicine,
3-39-22 Showa, Maebashi, Gunma 371-8511 Japan.
E-mail: tshinoza@showa.gunma-u.ac.jp
Clin Exp Rheumatol 2004; 22: 71-78.
© Copyright Clinical and Experimental
Rheumatology 2004.